Ovarian Cancer Vaccine Trial

This is a Phase II clinical trial of a novel pentavalent vaccine intended to elicit an immune response against the most common antigens over expressed on the surface of ovarian cancers and is being sponsored by the National Cancer Institute and the Gynecologic Oncology Group. The vaccine was developed at Memorial Sloan-Kettering Cancer Center. The clinical trial will test the ability of the vaccine to elicit protective antibodies that can kill the circulating tumor cells and micrometastases that remain and can cause tumor recurrence after all standard therapy is administered to the patient.

For complete information on the study entitled “A Phase III Randomized, Double-Blind Trial Of A Polyvalent Vaccine-KLH Conjugate (NSC 748933) + OPT-821 Versus OPT-821 In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Cancer Who Are In Second Or Third Complete Remission”, and a list of the investigational sites and principal investigators, please see the ClinicalTrials.gov website

http://www.clinicaltrials.gov/ct2/show/NCT00857545

Patient Resources Links: